Fig. 3From: Prime-boost vaccination strategy enhances immunogenicity compared to single pneumococcal conjugate vaccination in patients receiving conventional DMARDs, to some extent in abatacept but not in rituximab-treated patientsThe number of serotypes with putative protective levels (i.e., specific IgG concentration ≥ 1.3 μg/mL) after PCV13 and PCV13 + PPV23 in treatment groups and controlsBack to article page